Cargando…

Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study

AIMS: This study is a real world, observational study evaluating the treatment persistence of oral antiplatelet (OAP) therapy during a one-year follow-up in patients after an acute coronary syndrome (ACS). METHODS AND RESULTS: Data on diagnosis, comorbidities, follow-up, OAP treatment, reasons, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claeys, Marc J., Beauloye, Christophe, Pourbaix, Suzanne, Sinnaeve, Peter R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843130/ https://www.ncbi.nlm.nih.gov/pubmed/28122793 http://dx.doi.org/10.1093/ehjcvp/pvw043

Ejemplares similares

Real-World Use and Outcomes of Oral Antiplatelets Among Patients with Acute Coronary Syndrome: A Retrospective Cohort Study
por: Peasah, Samuel K., et al.
Publicado: (2021)

Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry
por: Marcucci, Rossella, et al.
Publicado: (2019)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Duration and clinical outcomes of dual antiplatelet therapy following percutaneous coronary intervention for acute coronary syndrome: A multicentre “real-world practice” registry-based study
por: Vergara-Uzcategui, Carlos E., et al.
Publicado: (2023)

Optimal duration of dual antiplatelet therapy for coronary artery disease
por: Kikkert, W. J., et al.
Publicado: (2018)

Renal dysfunction in STEMI-patients undergoing primary angioplasty: higher prevalence but equal prognostic impact in female patients; an observational cohort study from the Belgian STEMI registry
por: Gevaert, Sofie A, et al.
Publicado: (2013)

International patterns of dual antiplatelet therapy duration after acute coronary syndromes
por: Bueno, Héctor, et al.
Publicado: (2017)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
por: Zeymer, Uwe
Publicado: (2013)

Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
por: Berger, Jeffrey S.
Publicado: (2018)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
por: Cho, Min Soo, et al.
Publicado: (2017)

Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues
por: Verdoia, Monica, et al.
Publicado: (2020)

Impact of preprocedural coronary flow grade on duration of dual antiplatelet therapy in acute myocardial infarction
por: Kim, Yong Hoon, et al.
Publicado: (2021)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

Long-Term Use of Antiplatelet Therapy in Real-World Patients with Acute Myocardial Infarction: Insights from the PIPER Study
por: Degli Esposti, Luca, et al.
Publicado: (2018)

Evaluation of the association between admission systolic blood pressure and the choice of initial antiplatelet therapy for minor ischemic stroke in real‐world
por: Liu, Tingting, et al.
Publicado: (2022)

Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease
por: Krackhardt, Florian, et al.
Publicado: (2020)

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience
por: Rossini, Roberta, et al.
Publicado: (2020)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review
por: Carciotto, Gabriele, et al.
Publicado: (2023)

Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China
por: Liu, Xin, et al.
Publicado: (2019)

Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease
por: Krackhardt, Florian, et al.
Publicado: (2022)

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA
por: Wang, Yun, et al.
Publicado: (2019)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2015)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
por: Gozzo, Lucia, et al.
Publicado: (2017)

Introduction of new oral antiplatelet drugs in myocardial infarction hospital network: initial experience
por: Rakowski, Tomasz, et al.
Publicado: (2013)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome: Practical lessons from a review
por: ten Berg, J. M., et al.
Publicado: (2017)

Retrospective analysis of the bleeding risk induced by oral antiplatelet drugs during radiotherapy
por: Xi, Dan, et al.
Publicado: (2021)

Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
por: Jhang, Kai-Ming, et al.
Publicado: (2015)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Peripheral Arterial Disease: A Meta-Analysis
por: Ling, Hua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5knc9olje83m5rlm4fb8i1kqo1